Improved method of electrical stimulation could help treat damaged nerves

Functional electrical stimulation (FES) was developed to help return lost function to patients with upper and lower extremity injuries and spinal cord injuries, among other applications. However, the devices, which work by stimulating neuronal activity in nerve-damaged patients, have a potential shortcoming in that the electrical currents needed for the treatment to work can also send errant signals to surrounding nerves, resulting in painful side effects.

Earlier this fall, a plastic surgery research team at Beth Israel Deaconess Medical Center (BIDMC) and an engineering team from the Massachusetts Institute of Technology (MIT), described a new method of nerve stimulation that reduces the device's electrical threshold by 40 percent, compared with traditional FES therapy. Reported in the October 23 Advance On-line issue of the journal Nature Materials, the findings could help researchers develop a safer, more efficient FES therapy with fewer side effects.

“This new device works by manipulating the concentration of charged ions surrounding the nerve,” explains co-senior author Samuel J. Lin, MD, a surgeon in BIDMC's Divisions of Plastic Surgery and Otolaryngology and Assistant Professor of Surgery at Harvard Medical School. “This could potentially mean reduced risk to surrounding nerves because less electrical current is required to stimulate the affected nerve.” The researchers additionally discovered that they could use the device to block signals in nearby nerve fibers, which could help prevent unwanted muscle contractions.

The research team, led by Lin and MIT Associate Professor Jongyoon Han, PhD, determined that by altering calcium ion concentrations in the fluid surrounding the nerves they could adjust the electrical impulses.

“Nerve fibers fire their signals based on the message they receive from the interaction of ions, or charged particles,” explains coauthor Ahmed M.S. Ibrahim, MD, a Research Fellow in BIDMC's Divisions of Plastic Surgery and Otolaryngology. “We wanted to achieve the lowest current possible that would still result in positive results.” After testing the manipulation of sodium and potassium ions, the researchers determined that consistent results could be achieved by removing positively charged calcium ions from the fluid surrounding the nerves.

The newly designed method not only prevents electrical impulses from traveling along a nerve but also uses significantly less current required by existing FES therapy. “This could be of particular benefit for the treatment of patients with various forms of paralysis,” explains Lin. “The nerves that control movements and the sensory nerves that carry pain signals are extremely close together, so existing FES therapy has had limitations.”

The researchers conducted their study of this new electrochemical-stimulation method in the nerves of frogs and plan to later test it in mammalian nerves.

“This is an important step towards the design of a device to aid in helping patients suffering from nerve paralysis and chronic neurological conditions,” say Lin. “By bringing together biomedical and engineering research teams we have been able to successfully develop this new technique. Going forward, these types of collaborations will be absolutely crucial to creating new clinical treatments and enhancing patient care.”

In addition to Lin, Han and Ibrahim, study coauthors include Rohat Melik of MIT, Amr N. Rabie of BIDMC and Ain Shams University, Cairo, Egypt; David Moses of Rice University, Houston, TX; and Ara Tan of the University of Minnesota.

This study was supported, in part, by a Harvard Catalyst grant from the Harvard Clinical and Translational Science Center (National Institutes of Health) and the Massachusetts Institute of Technology.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox.